B2M and amyloidosis: A comprehensive meta-analysis of the effectiveness of high-flux dialysis and convective dialysis modalities, including HDF and hemofiltration, in removing beta-2-microglobulin (β2M), a middle-molecular-weight solute implicated in dialysis-related amyloidosis and adverse cardiovascular outcomes in end-stage kidney disease (ESKD), was published in 2018 [29].